Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McGill University

$92,119.00

Rapidly-Gelling, Guanosine 5' Diphosphate-Crosslinked Injectable Chitosan Sponges to Promote Oligodendrocyte Progenitor Cells' Differentiation Post-Spinal Cord Injuries

FY 2016-17

Summary
In Canada, there are approximately 86,000 Canadians living with spinal cord injuries (SCI). The economic burden caused bySCI is immense, costing Canada an estimated $3.6 billion/Y. The initial trauma causes a contusion injury to the spinal cordresulting in damage to neurons and oligodendrocytes (OLGs). Secondary to trauma, there is additional neuronal and axonalloss, and damage to myelin and glia. The loss of myelin surrounding intact axons (demyelination) can result in functional lossbecause of the inability of these axons to effectively conduct nerve impulses. At present there are no effective treatments forSCI, and although many researchers are interested in neural regeneration, none are focused on developing biomaterials totarget remyelination post-SCI. Therefore, the overall objective of this proposal is to use an injectable scaffold containingneurotrophic factors to promote the differentiation of endogenous OPCs and improve remyelination and neurological functionpost-SCI. We successfully developed a novel, rapidly-gelling, injectable chitosan sponge using Guanosine 5-diphosphate(GDP). The sponges gel in less than 2 seconds, a highly desirable property to ensure localization at the site of injection.Moreover, the sponges were found to have very desirable physicochemical properties and excellent cytocompatibility. BrainDerived Neurotrophic Factor (BDNF) was successfully entrapped and released from the sponges in a controlled manner forup to 3 weeks. Furthermore, we demonstrated the successful attachment and differentiation of rat OPCs' on the chitosansponges. Further studies are still required using rat OPCs to investigate myelination on the sponges. Furthermore, fetal andadult human OPCs survival and differentiation on the sponges will be assessed. Finally, chitosan sponges will be injected ina contused mouse spinal cord model to study remyelination and recovery of neurological functions.
Program
Collaborative Health Research Projects
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
462506-2014
Name nom
Tabrizian, Maryam
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2014
Award amount
92119
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
3
Nb partie
3
Application title
Rapidly-Gelling, Guanosine 5' Diphosphate-Crosslinked Injectable Chitosan Sponges to Promote Oligodendrocyte Progenitor Cells' Differentiation Post-Spinal Cord Injuries
Keyword
NSERC
Application summary
In Canada, there are approximately 86,000 Canadians living with spinal cord injuries (SCI). The economic burden caused bySCI is immense, costing Canada an estimated $3.6 billion/Y. The initial trauma causes a contusion injury to the spinal cordresulting in damage to neurons and oligodendrocytes (OLGs). Secondary to trauma, there is additional neuronal and axonalloss, and damage to myelin and glia. The loss of myelin surrounding intact axons (demyelination) can result in functional lossbecause of the inability of these axons to effectively conduct nerve impulses. At present there are no effective treatments forSCI, and although many researchers are interested in neural regeneration, none are focused on developing biomaterials totarget remyelination post-SCI. Therefore, the overall objective of this proposal is to use an injectable scaffold containingneurotrophic factors to promote the differentiation of endogenous OPCs and improve remyelination and neurological functionpost-SCI. We successfully developed a novel, rapidly-gelling, injectable chitosan sponge using Guanosine 5-diphosphate(GDP). The sponges gel in less than 2 seconds, a highly desirable property to ensure localization at the site of injection.Moreover, the sponges were found to have very desirable physicochemical properties and excellent cytocompatibility. BrainDerived Neurotrophic Factor (BDNF) was successfully entrapped and released from the sponges in a controlled manner forup to 3 weeks. Furthermore, we demonstrated the successful attachment and differentiation of rat OPCs' on the chitosansponges. Further studies are still required using rat OPCs to investigate myelination on the sponges. Furthermore, fetal andadult human OPCs survival and differentiation on the sponges will be assessed. Finally, chitosan sponges will be injected ina contused mouse spinal cord model to study remyelination and recovery of neurological functions.